These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 284720)

  • 41. Defective methionine metabolism in cirrhosis: relation to severity of liver disease.
    Marchesini G; Bugianesi E; Bianchi G; Fabbri A; Marchi E; Zoli M; Pisi E
    Hepatology; 1992 Jul; 16(1):149-55. PubMed ID: 1377658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Plasma concentration and elimination behavior of the cardiac glycoside meproscillarin in patients with liver cirrhosis].
    Burkert K; Beckmann H
    Z Gastroenterol; 1983 Jan; 21(1):34-40. PubMed ID: 6845784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Higher levels of serum aminoterminal type III procollagen peptide, and laminin in alcoholic than in nonalcoholic cirrhosis of equal severity.
    Lotterer E; Gressner AM; Kropf J; Grobe E; von Knebel D; Bircher J
    J Hepatol; 1992 Jan; 14(1):71-7. PubMed ID: 1737919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol.
    Bannwarth B; Netter P; Lapicque F; Gillet P; Péré P; Boccard E; Royer RJ; Gaucher A
    Br J Clin Pharmacol; 1992 Jul; 34(1):79-81. PubMed ID: 1633071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Data point weighting in pharmacokinetic analysis: intravenous paracetamol in man.
    Clements JA; Prescott LF
    J Pharm Pharmacol; 1976 Sep; 28(9):707-9. PubMed ID: 10395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose.
    Gregoire N; Hovsepian L; Gualano V; Evene E; Dufour G; Gendron A
    Clin Pharmacol Ther; 2007 Mar; 81(3):401-5. PubMed ID: 17339870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of malaria infection on paracetamol disposition in the rat.
    Mansor SM; Edwards G; Roberts PJ; Ward SA
    Biochem Pharmacol; 1991 Jun; 41(11):1707-11. PubMed ID: 2043159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. alpha 2-Plasmin inhibitor metabolism in patients with liver cirrhosis.
    Knot EA; Drijfhout HR; ten Cate JW; de Jong E; Iburg AH; Kahlé LH; Grijm R
    J Lab Clin Med; 1985 Mar; 105(3):353-8. PubMed ID: 3973471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis.
    Lebrault C; Berger JL; D'Hollander AA; Gomeni R; Henzel D; Duvaldestin P
    Anesthesiology; 1985 May; 62(5):601-5. PubMed ID: 2859815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver damage and plasma concentrations of paracetamol and its metabolites after paracetamol overdosage in mice.
    Esteban A; Satorres J; Mayole MJ; Graells ML; Pérez-Mateo M
    Methods Find Exp Clin Pharmacol; 1993 Mar; 15(2):125-30. PubMed ID: 8487595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation.
    Scavone JM; Greenblatt DJ; LeDuc BW; Blyden GT; Luna BG; Harmatz JS
    Pharmacology; 1990; 40(2):77-84. PubMed ID: 2345775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cimetidine clearance and bioavailability in hepatic cirrhosis.
    Sonne J; Poulsen HE; Døssing M; Larsen NE; Andreasen PB
    Clin Pharmacol Ther; 1981 Feb; 29(2):191-7. PubMed ID: 7460483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease.
    Elefsiniotis IS; Skounakis M; Vezali E; Pantazis KD; Petrocheilou A; Pirounaki M; Papatsibas G; Kontou-Kastellanou C; Moulakakis A
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):525-30. PubMed ID: 16607149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage.
    Schiødt FV; Ott P; Christensen E; Bondesen S
    Clin Pharmacol Ther; 2002 Apr; 71(4):221-5. PubMed ID: 11956504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temporal variations in paracetamol absorption and metabolism in man.
    Kamali F; Fry JR; Bell GD
    Xenobiotica; 1987 May; 17(5):635-41. PubMed ID: 3604267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of encainide in patients with cirrhosis.
    Wensing G; Mönig H; Ohnhaus EE; Hoensch HP
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioequivalence and Safety of Twice-Daily Sustained-Release Paracetamol (Acetaminophen) Compared With 3- and 4-Times-Daily Paracetamol: A Repeat-Dose, Crossover Pharmacokinetic Study in Healthy Volunteers.
    Liu DJ; Collaku A
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):77-86. PubMed ID: 28815997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elimination of pindolol in liver disease.
    Ohnhaus EE; Münch U; Meier J
    Eur J Clin Pharmacol; 1982; 22(3):247-51. PubMed ID: 7106158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Femoxetine clearance in patients with liver cirrhosis.
    Hansen BA; Mengel H; Keiding S; Lund J
    Acta Pharmacol Toxicol (Copenh); 1984 Nov; 55(5):386-90. PubMed ID: 6528808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fibronectin decrease in liver cirrhosis is related to spleen size.
    de Angelis V; Zambon M; Toffolo L; Donada C; Molaro GL; Zuin R
    Klin Wochenschr; 1988 Jun; 66(12):524-6. PubMed ID: 3419082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.